NIMH hosts Pittsburgh forum on depression/physical illness connection

March 19, 2001

National and Local Experts to Address Depression's Toll on Other Illnesses

Washington, D.C. -- (March 20, 2001) -- Treatment of depression, which often accompanies other major illnesses, such as cancer, diabetes, heart disease, stroke, HIV/AIDS, and Parkinson's disease, can improve health outcomes for both illnesses.

Research on the link between depression and other serious illnesses is the focus of a meeting sponsored by the National Institute of Mental Health (NIMH). The meeting, The Unwanted Cotraveler: Depression's Toll on Other Illnesses, will be from 9:30 a.m. to 4:30 p.m. on Monday March 26, 2001, at the Westin Convention Center in Pittsburgh: Advocates, patients, doctors, other care providers, and policy makers are invited to hear about scientific advances linking depression and other illnesses, and the role that treating depression plays in improving the course of the other disease. In addition, participants will offer ideas for shaping the Institute's research agenda, as well as informing educational and communication efforts for improving health care.

NIMH director Steven E. Hyman, M.D., who will provide an opening overview and closing comments for the meeting, said, "The important news is that depression, alone or occurring with another illness, is a treatable disorder. Not only may relief from depression help a patient adhere to complex treatment plans for other illnesses, and improve their quality of life, but researchers are tracing the biological aspects of depression that could affect these other illnesses at the physiological and cellular levels. The primary purpose of this conference is to disseminate this information to every patient who needs it, and into every doctor's office, hospital and nursing home where the suffering of depression can be alleviated."

Co-hosts for the meeting are the University of Pittsburgh and the Jewish Healthcare Foundation.

David J. Kupfer, M.D., Thomas Detre, Professor and Chairman, Department of Psychiatry, University of Pittsburgh Medical Center, will chair the meeting. Speakers include: · Mary Korytkowski, M.D., University of Pittsburgh School of Medicine, on diabetes; · Dennis Charney, M.D., NIMH Intramural Research Program, on cardiovascular disease; · Andrew Baum, Ph.D., University of Pittsburgh Cancer Center, on cancer; · William M. McDonald, M.D., Emory University School of Medicine, on Parkinson's and other neurological diseases; and · Robert Johnson, M.D., New Jersey Medical School, on HIV/AIDS.
Sen. Arlen Specter, (R) Pennsylvania, and Rep. Patrick J. Kennedy, (D) Rhode Island, will deliver keynote speeches at the luncheon. Rep. Kennedy will speak about his personal fight with depression. Other speakers include Charles Curie, Deputy Secretary, Office of Mental Health and Substance Abuse Services, Pennsylvania Department of Public Welfare; Lydia Lewis, Executive Director, National Depressive and Manic-Depressive Association; and Steven A. Schroeder, M.D., President, The Robert Wood Johnson Foundation.

Researchers will speak and lead discussions on how depression alters various neurotransmitters, which are critical to the progression of Parkinson's and other neurological diseases. As another example, depression induces stress hormones that can affect the cardiovascular system and is associated with changes in platelet function that may be important in people who have heart disease. Depression's physiological effects also include the suppression of the immune system, which may adversely alter the course of cancer and HIV/AIDS. The interconnections go on, with studies linking depression and obesity and diabetes, as well as intriguing findings showing common genetic patterns in depression and diabetes. Current treatments provide relief from depression's symptoms which include sadness, loss of interest or pleasure in activities that were once enjoyed, change in appetite or weight, difficulty sleeping or oversleeping, physical slowing or agitation, energy loss, feelings of worthlessness or inappropriate guilt, difficulty thinking or concentrating, and recurrent thoughts of death or suicide.

The conference will include plenary sessions to share NIMH scientific findings on depression and its treatment, including treatment approaches tailored to the needs of people with co-existing illnesses. Breakout sessions will provide participants an opportunity to discuss ways to diagnose and treat depression that are appropriate to each illness, and how treating depression can improve health outcome for the other illness and quality of life for patients.
For more on the meeting, including registration information and a complete agenda, visit:

NIMH is the Federal agency responsible for supporting and conducting research on mental disorders. NIMH is sponsoring a series of meetings, nationwide, to seek input from the American public about its perceptions of research needs and opportunities. This Forum has been developed in partnership with the Western State Psychiatric Institute and Clinic at the University of Pittsburgh Medical Center, the Jewish Healthcare Foundation, patient and professional organizations, universities, and business leaders, as well as state and local agencies. The ideas and questions generated at this meeting will inform NIMH's research priorities and outreach efforts to ensure relevance and responsiveness to America's health needs.

NIMH is one of 25 components that make up the National Institutes of Health, part of the U.S. Department of Health and Human Services. For information about NIMH and its programs, please check out our web site at, or e-mail, write or phone us.

NIMH Public Inquiries
6001 Executive Boulevard, Rm. 8184, MSC 9663
Bethesda, MD 20892-9663 U.S.A.
Voice 301-443-4513; Fax 301-443-4279

For additional information, contact:
Marilyn Weeks or Rayford Kytle

NIH/National Institute of Mental Health

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to